SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS shares experienced downward pressure alongside widespread community debate triggered by third-party survival models shared on social media, which challenged the previously high success expectations for the REGAL trial. While some traders interpreted the decline as a coordinated manipulation effort to shake out weak hands, others viewed it as a necessary rebalancing, with many long-term shareholders emphasizing that the core clinical thesis and trial dynamics remain unchanged.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing downward price pressure driven by investor disappointment regarding the efficacy data for its sonelokimab therapy in psoriatic arthritis, as well as concerns over the company's decision to pursue a solo commercialization strategy involving potential share dilution. While some traders view the current stock price as an attractive buying opportunity due to the company's strong cash position and the upcoming FDA filing for hidradenitis suppurativa, others are skeptical of management's communication and the drug's ability to compete in a crowded market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversation around DJT is dominated by intense political polarization, centering on criticisms of Donald Trump's conduct during the 25th anniversary of 9/11 and skepticism regarding his campaign pledge to issue a financial dividend to citizens. Traders are divided between supporters defending his leadership and critics highlighting concerns over his campaign promises, potential ethical issues, and the company's financial performance.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to significant community backlash and price decline following the company's announcement of a new $1 billion at-the-market equity offering program. Traders are debating the necessity of this dilution given the company's existing cash balance, while expressing frustration over recent insider selling and the lack of immediate commercial revenue.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

The conversation surrounding Onyxcoin is heavily polarized, with many traders labeling the asset a "pump and dump" scheme due to consistent price volatility and skepticism regarding its leadership. Conversely, some community members remain bullish, focusing on technical developments like the Onyx Mesh infrastructure, ongoing staking rewards, and potential institutional adoption through the integration of Chain's technology.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently experiencing high volatility driven by speculation regarding potential peptide product launches and broader global expansion, alongside community debate over short interest and institutional activity. Investors remain divided, with some highlighting the company's long-term growth potential and data-driven platform, while others focus on regulatory risks and intense fluctuations in trading volume.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF is trending as traders react to its significant year-to-date gains and ongoing geopolitical instability in the Middle East, particularly around the Strait of Hormuz. Community discussion centers on the potential for continued upside driven by shipping rate volatility and the scarcity of tanker capacity, alongside debate regarding the risks of entering the trade at current parabolic price levels.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The energy sector is trending due to rising crude prices driven by escalating tensions in the Middle East and concerns over supply disruptions at the Strait of Hormuz. While some traders are expressing uncertainty and debating the impact of ongoing geopolitical conflict and potential diplomatic negotiations on future performance, the sector continues to show relative strength with significant year-to-date gains.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is trending following an earnings report that exceeded analyst expectations for both revenue and EPS, coupled with upward-revised guidance driven by robust demand for optical networking and AI infrastructure. Despite the strong results, the stock is experiencing high volatility as traders react to the news and ongoing uncertainty regarding macroeconomic conditions.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is seeing intense volatility as investors react to a significant multi-billion dollar data center deal with Anthropic, leading to heavy trading volume and debate over whether the stock is being manipulated or undergoing a strategic re-rating as an AI infrastructure play. The community remains deeply divided, with many debating if the recent price action represents a classic shakeout of weak hands or a failure of the stock to sustain momentum despite positive long-term contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing...

Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline

Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff DeadlinePR NewswireRADNOR, Pa., Sept. 11, 2026Did you buy HIMS...

HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, both dates inclusive (the Class Period), have until November 2, 2026 to seek appointment as lead plaintiff of the...

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS PR Newswire SAN FRANCISCO, Sept. 10, 2026 SAN...

Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline

Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026...

Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Here's Why Teladoc's Integrated Care Business Deserves More Attention

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire NEW YORK, Sept. 6, 2026 NEW YORK...

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion 

Equity

Bearish Sentiment

Favorable

Unfavorable

Delayed

Hims & Hers ($HIMS) is bracing for a pivotal FDA advisory meeting on July 23-24 that will decide whether seven peptides get added to the compounding list. How do you think the FDA rules? Vote and explain your reasoning in the comments.

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for $HIMS. How do you think it goes?

Stocktwits

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for 

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIMS Hims & Hers Health Inc

Fundamentals

Latest HIMS News